Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life

Ilaria Cuomo,1,2 Georgios D Kotzalidis,1 Simone de Persis,2 Daria Piacentino,1 Filippo Perrini,2 Emanuela Amici,2 Sergio De Filippis1,2 1Department of Neurosciences, Mental Health, and Sensory Organs (NESMOS), Sapienza School of Medicine and Psychology, Sant’Andrea Hospital, Rome, Italy;...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cuomo I, Kotzalidis GD, de Persis S, Piacentino D, Perrini F, Amici E, De Filippis S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Psychosis Schizophrenia spectrum and other psychotic disorders Bipolar disorder Long-acting injectable antipsychotic drugs Aripiprazole once-monthly Paliperidone once-monthly Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/bd4b5f7866b44701a1fdba29672c6bc3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bd4b5f7866b44701a1fdba29672c6bc3
record_format	dspace
spelling	oai:doaj.org-article:bd4b5f7866b44701a1fdba29672c6bc32021-12-02T07:34:57ZHead-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life1178-2021https://doaj.org/article/bd4b5f7866b44701a1fdba29672c6bc32018-06-01T00:00:00Zhttps://www.dovepress.com/head-to-head-comparison-of-1-year-aripiprazole-long-acting-injectable--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Ilaria Cuomo,1,2 Georgios D Kotzalidis,1 Simone de Persis,2 Daria Piacentino,1 Filippo Perrini,2 Emanuela Amici,2 Sergio De Filippis1,2 1Department of Neurosciences, Mental Health, and Sensory Organs (NESMOS), Sapienza School of Medicine and Psychology, Sant’Andrea Hospital, Rome, Italy; 2Department of Neuropsychiatry, Villa von Siebenthal Neuropsychiatric Hospital and Clinic, Genzano di Roma, Rome, Italy Background: To overcome nonadherence in patients with psychosis switch to long-acting injectable (LAI) antipsychotic formulations is adopted. Most oral versus LAI comparisons showed similar antipsychotic responses. Psychoses often overlap with substance use disorder (SUD). Head-to-head LAI comparisons have hitherto focused only on non-comorbid populations. Objective: The objective of this study was to compare two LAIs, administered for 12 months, in initially hospitalized patients with psychosis comorbid with SUD in their clinical and quality of life (QoL) outcomes. Patients and methods: Inpatients were recruited during 2016 and switched randomly to 400 mg intramuscular aripiprazole monohydrate (AM) (N=50) or to 100 mg intramuscular paliperidone palmitate (PP) once-monthly (N=51); patients were discharged and followed up for 12 months. Patients were rated at baseline and after 1 year through the Clinical Global Impression scale – severity (CGIs), substance craving intensity was rated through a visual analog scale for substance craving, and QoL through the World Health Organization (WHOQOL-BREF) scale. We addressed confounders with backward stepwise logistic regression and three-way analysis of variance. Results: PP were older and had more cases of schizophrenia spectrum and less bipolar disorders than AM, but AM had a stronger craving for substances at baseline. Both LAIs were associated with significant improvements in all outcomes, with AM displaying stronger effect sizes than PP. The two groups did not differ on baseline WHOQOL-BREF scores in any domain, but at the 1-year follow-up, AM fared better on all domains. The two groups did not differ in final severity, but PP scored higher than AM in craving at the 1-year endpoint. Limitation: The CGIs is not a refined tool for severity and the substance craving may be subject to recall bias. Conclusion: 1-year AM and PP was followed by improved clinical status and QoL and reduced substance craving in a population with psychosis and SUD comorbidity. AM, compared to PP, improved craving and QoL at the 1-year follow-up. Keywords: psychosis, schizophrenia spectrum and other psychotic disorders, bipolar disorder, long-acting injectable antipsychotic drugs, aripiprazole once-monthly, paliperidone once-monthlyCuomo IKotzalidis GDde Persis SPiacentino DPerrini FAmici EDe Filippis SDove Medical PressarticlePsychosisSchizophrenia spectrum and other psychotic disordersBipolar disorderLong-acting injectable antipsychotic drugsAripiprazole once-monthlyPaliperidone once-monthlyNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 1645-1656 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Psychosis Schizophrenia spectrum and other psychotic disorders Bipolar disorder Long-acting injectable antipsychotic drugs Aripiprazole once-monthly Paliperidone once-monthly Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Psychosis Schizophrenia spectrum and other psychotic disorders Bipolar disorder Long-acting injectable antipsychotic drugs Aripiprazole once-monthly Paliperidone once-monthly Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Cuomo I Kotzalidis GD de Persis S Piacentino D Perrini F Amici E De Filippis S Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
description	Ilaria Cuomo,1,2 Georgios D Kotzalidis,1 Simone de Persis,2 Daria Piacentino,1 Filippo Perrini,2 Emanuela Amici,2 Sergio De Filippis1,2 1Department of Neurosciences, Mental Health, and Sensory Organs (NESMOS), Sapienza School of Medicine and Psychology, Sant’Andrea Hospital, Rome, Italy; 2Department of Neuropsychiatry, Villa von Siebenthal Neuropsychiatric Hospital and Clinic, Genzano di Roma, Rome, Italy Background: To overcome nonadherence in patients with psychosis switch to long-acting injectable (LAI) antipsychotic formulations is adopted. Most oral versus LAI comparisons showed similar antipsychotic responses. Psychoses often overlap with substance use disorder (SUD). Head-to-head LAI comparisons have hitherto focused only on non-comorbid populations. Objective: The objective of this study was to compare two LAIs, administered for 12 months, in initially hospitalized patients with psychosis comorbid with SUD in their clinical and quality of life (QoL) outcomes. Patients and methods: Inpatients were recruited during 2016 and switched randomly to 400 mg intramuscular aripiprazole monohydrate (AM) (N=50) or to 100 mg intramuscular paliperidone palmitate (PP) once-monthly (N=51); patients were discharged and followed up for 12 months. Patients were rated at baseline and after 1 year through the Clinical Global Impression scale – severity (CGIs), substance craving intensity was rated through a visual analog scale for substance craving, and QoL through the World Health Organization (WHOQOL-BREF) scale. We addressed confounders with backward stepwise logistic regression and three-way analysis of variance. Results: PP were older and had more cases of schizophrenia spectrum and less bipolar disorders than AM, but AM had a stronger craving for substances at baseline. Both LAIs were associated with significant improvements in all outcomes, with AM displaying stronger effect sizes than PP. The two groups did not differ on baseline WHOQOL-BREF scores in any domain, but at the 1-year follow-up, AM fared better on all domains. The two groups did not differ in final severity, but PP scored higher than AM in craving at the 1-year endpoint. Limitation: The CGIs is not a refined tool for severity and the substance craving may be subject to recall bias. Conclusion: 1-year AM and PP was followed by improved clinical status and QoL and reduced substance craving in a population with psychosis and SUD comorbidity. AM, compared to PP, improved craving and QoL at the 1-year follow-up. Keywords: psychosis, schizophrenia spectrum and other psychotic disorders, bipolar disorder, long-acting injectable antipsychotic drugs, aripiprazole once-monthly, paliperidone once-monthly
format	article
author	Cuomo I Kotzalidis GD de Persis S Piacentino D Perrini F Amici E De Filippis S
author_facet	Cuomo I Kotzalidis GD de Persis S Piacentino D Perrini F Amici E De Filippis S
author_sort	Cuomo I
title	Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
title_short	Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
title_full	Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
title_fullStr	Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
title_full_unstemmed	Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
title_sort	head-to-head comparison of 1-year aripiprazole long-acting injectable (lai) versus paliperidone lai in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/bd4b5f7866b44701a1fdba29672c6bc3
work_keys_str_mv	AT cuomoi headtoheadcomparisonof1yeararipiprazolelongactinginjectablelaiversuspaliperidonelaiincomorbidpsychosisandsubstanceusedisorderimpactonclinicalstatussubstancecravingandqualityoflife AT kotzalidisgd headtoheadcomparisonof1yeararipiprazolelongactinginjectablelaiversuspaliperidonelaiincomorbidpsychosisandsubstanceusedisorderimpactonclinicalstatussubstancecravingandqualityoflife AT depersiss headtoheadcomparisonof1yeararipiprazolelongactinginjectablelaiversuspaliperidonelaiincomorbidpsychosisandsubstanceusedisorderimpactonclinicalstatussubstancecravingandqualityoflife AT piacentinod headtoheadcomparisonof1yeararipiprazolelongactinginjectablelaiversuspaliperidonelaiincomorbidpsychosisandsubstanceusedisorderimpactonclinicalstatussubstancecravingandqualityoflife AT perrinif headtoheadcomparisonof1yeararipiprazolelongactinginjectablelaiversuspaliperidonelaiincomorbidpsychosisandsubstanceusedisorderimpactonclinicalstatussubstancecravingandqualityoflife AT amicie headtoheadcomparisonof1yeararipiprazolelongactinginjectablelaiversuspaliperidonelaiincomorbidpsychosisandsubstanceusedisorderimpactonclinicalstatussubstancecravingandqualityoflife AT defilippiss headtoheadcomparisonof1yeararipiprazolelongactinginjectablelaiversuspaliperidonelaiincomorbidpsychosisandsubstanceusedisorderimpactonclinicalstatussubstancecravingandqualityoflife
_version_	1718399362902523904

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life

Ejemplares similares